Department of Medical Genetics-HediChaker Hospital, Sfax-Tunisia.
Laboratory of Histology, Faculty of Medicine of Sfax, Sfax-Tunisia.
Afr Health Sci. 2022 Jun;22(2):318-322. doi: 10.4314/ahs.v22i2.35.
The fms-like tyrosine kinase 3 (FLT3) gene belong to the class III receptor tyrosine kinases witch is predominantly expressed on hematopoietic progenitor cells, and plays an important role in haematopoiesis. Targeting the FMS-like tyrosine kinase receptor-3 (FLT3) in acute leukemia is mainly important. Therefore, activating mutations in FLT3, primarily the FLT3-internal tandem duplication (FLT3-ITD), was used as a prognostic marker especially in myeloid leukemia; however, in ALL, the prognostic relevance of FLT3 mutations is less clear.
This study was conducted to evaluate the frequency of FLT3-ITD mutation in Tunisian childhood acute lymphoblastic leukemia, and to correlate this mutation with prognostic parameters.
Genomic DNA was extracted from EDTA-anticoagulant blood samples from a total of 25 children suffering from acute lymphoblastic leukemia (ALL). After DNA extraction, the polymerase chain reaction using specific primers was conducted to screen the FLT3-ITD.
In acute lymphoblastic leukemia (ALL), 9 cases with LAL-B were detected and the median age is 13 years. Chromosome abnormalities were detected in 5 with ALL and are correlated with worse prognosis (very high risk and relapse). At molecular lever, never FLT3-ITD was detected.
Our findings suggest that FLT3 mutations are not common in Tunisian childhood ALL and thus do not affect clinical outcome.
fms 样酪氨酸激酶 3(FLT3)基因属于 III 类受体酪氨酸激酶,主要表达于造血祖细胞,在造血过程中发挥重要作用。靶向急性白血病中的 FMS 样酪氨酸激酶受体-3(FLT3)尤为重要。因此,FLT3 的激活突变,主要是 FLT3 内部串联重复(FLT3-ITD),主要作为髓性白血病的预后标志物;然而,在 ALL 中,FLT3 突变的预后相关性尚不清楚。
本研究旨在评估 FLT3-ITD 突变在突尼斯儿童急性淋巴细胞白血病中的发生率,并探讨该突变与预后参数的相关性。
从 25 例患有急性淋巴细胞白血病(ALL)的儿童的 EDTA 抗凝血液样本中提取基因组 DNA。DNA 提取后,采用特异性引物的聚合酶链反应(PCR)筛选 FLT3-ITD。
在急性淋巴细胞白血病(ALL)中,共检测到 9 例 LAL-B,中位年龄为 13 岁。5 例 ALL 检测到染色体异常,与预后较差(极高危和复发)相关。在分子水平上,从未检测到 FLT3-ITD。
我们的研究结果表明,FLT3 突变在突尼斯儿童 ALL 中并不常见,因此不会影响临床结局。